Financial Snapshot
What does Xylem financial health look like in one scorecard?
Strong. The strongest factor is margin expansion and cash outlook, while the main concern is slower 2026 revenue guidance and lower latest-period cash.
Xylem financial health looks strong based on full-year 2025 results and 2026 guidance. The verdict blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency, so it is useful for essays, case studies, and valuation work, including the Xylem Inc. (XYL): History, Ownership, Mission, How It Works & Makes Money background.
Adjusted EPS was $508 in full-year 2025, up 190%, so earnings grew faster than revenue. Free cash flow deserves the first deeper look because it ties directly to reinvestment, debt capacity, and valuation.
Revenue and earnings quality
Are Xylem revenue and earnings growth high quality?
Strong. The clearest confirmation is that full-year 2025 adjusted EPS growth of $508 outpaced revenue growth, while Q4 2025 orders and backlog stayed strong enough to support 2026 visibility. The main divergence is the softer 2026-03-31 revenue snapshot.
Xylem’s growth looks more than just bigger sales because profitability improved faster than revenue in full-year 2025. Investors compare revenue durability with operating income, net income, and EPS across compatible annual periods to see whether growth is turning into real earnings power, not just top-line expansion.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $90B in full-year 2025, up 60% reported and 50% organic | Full-year 2024 revenue, not provided | Organic growth | Repeatable if demand, pricing, and execution hold up |
| Operating Income | Latest verified value not provided; Q4 2025 margin improved on productivity savings and strong price realization | Previous comparable value not provided | Operating leverage shown by margin support | Suggests the business is converting growth into better profitability |
| Net Income | $957M attributable to Xylem in full-year 2025 | Previous comparable value not provided | Verified operating, interest, tax, and unusual-item effects not fully provided | Confirms earnings strength, but the change drivers are only partly visible |
| Diluted EPS | $508 in full-year 2025 | Previous comparable diluted EPS not provided | Earnings grew faster than revenue | Shareholders received stronger per-share growth than sales growth alone |
How durable is Xylem's revenue growth?
Durability looks solid. The strongest signal is $24B Q4 2025 orders and a $4615B backlog, with approximately 600% expected to convert to revenue in 2026. The biggest limitation is the early 2026 softness in the latest quarter snapshot.
- Demand Quality: Recurring municipal, industrial, utility, digital, treatment, and services demand supports visibility, especially when it shows up in orders and backlog.
- Pricing and Volume: Q4 2025 revenue was driven by productivity savings and strong price realization; the price-volume split is otherwise unavailable.
- Diversification: Verified mix spans municipal, industrial, utility, digital, treatment, and services, which helps reduce dependence on one demand stream.
That sets up the next question for profitability and cash conversion.
Cash Conversion
Do Xylem margins convert into cash flow?
Yes, Xylem’s margin improvement is being supported by cash generation, but the latest 2026-03-31 operating and free cash flow growth data is too noisy to call it a trend. Full-year 2025 adjusted EBITDA margin was 22.2%, up 330 basis points over two years, and 2026 free cash flow margin is forecast at 10.2%–11.0%.
Gross margin shows product economics, operating margin shows how well scale and overhead are controlled, and net margin shows what is left after interest and taxes. For Xylem, the margin story is driven by pricing realization, productivity savings, and over $140M in Evoqua cost synergies, while cash conversion depends on operating cash flow, capital expenditure, and free cash flow rather than net income alone.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Unavailable; not supplied. | Unavailable; not supplied. | Pricing realization and productivity savings were cited, but no verified gross margin figure was supplied. | Suggests product economics improved, but the exact gross margin trend cannot be confirmed here. |
| Operating Margin | Adjusted EBITDA margin 22.2%, full-year 2025 | Full-year 2023 implied lower by 330 basis points over two years | Pricing realization, productivity savings, and over $140M in Evoqua cost synergies after full integration completed 18 months ahead of schedule. | Shows scale and integration are improving operating efficiency. |
| Net Margin | Unavailable; not supplied. | Unavailable; not supplied. | No verified net income, interest, tax, or unusual-item margin bridge was supplied. | Final profitability cannot be confirmed from the provided data. |
| Operating Cash Flow | 2026-03-31 warning data: Operating Cash Flow Growth -8011% | Unavailable; not supplied. | Latest quarter signal is distorted; no verified working-capital detail was supplied. | Does not yet prove earnings fail to convert into cash. |
| Free Cash Flow | 2026 free cash flow margin forecast 10.2%–11.0% | Unavailable; not supplied. | Capital expenditure is implied, but no dollar free cash flow value was supplied. | Leaves room for reinvestment and financing if the forecast holds. |
What most affects Xylem’s cash conversion?
The biggest verified driver is margin expansion from pricing, productivity, and over $140M in Evoqua synergies, but the latest quarter’s cash growth data is too volatile to separate structural change from temporary noise.
- Main Driver: Synergy capture and productivity gains look structural because full Evoqua integration finished 18 months early.
- Evidence Gap: The supplied data does not include gross margin, net margin, or detailed working-capital movements.
- Metric to Monitor: Watch operating cash flow and free cash flow margin against the 10.2%–11.0% forecast.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For company background, see Xylem Inc. (XYL): History, Ownership, Mission, How It Works & Makes Money.
Liquidity Check
Can Xylem Inc. balance sheet support its obligations and investment needs?
Mixed. Xylem Inc. has decent near-term liquidity, but the main concern is rising net debt and a heavier acquisition-linked asset base. The strongest protection is its $403B in current assets versus $276B in current liabilities; the main financing concern is $113B net debt at 2026-03-31.
Cash alone is not enough. Investors should weigh working capital, asset quality, debt service, solvency, liquidity, and refinancing together because a healthy cash balance can still sit alongside high leverage or weak assets. For a related ownership view, Exploring Xylem Inc. (XYL) Investor Profile: Who's Buying and Why? helps connect balance-sheet strength with investor behavior.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | At 2026-03-31, cash and cash equivalents were $80800M, total current assets were $403B, and total current liabilities were $276B. | Mixed | Near-term obligations look manageable, but cash is not large enough to cover all needs without relying on other current assets. |
| Total and Net Debt | Total debt was $194B and net debt was $113B at 2026-03-31; short term debt was $53100M and long term debt was $141B. | Mixed | Leverage is meaningful, so balance-sheet flexibility is narrower than the gross debt figure alone suggests. |
| Debt Service and Refinancing | Interest expense was $400M at 2026-03-31; no maturity schedule, rates, or covenant data were supplied. | Mixed | Debt service is visible, but refinancing pressure cannot be fully judged from the supplied data. |
| Asset Quality | Goodwill and intangible assets were $1051B versus total assets of $1695B at 2026-03-31. | Weak | A large acquisition-related asset base raises impairment and integration risk if performance weakens. |
| Liabilities and Equity | Total liabilities and shareholders' equity were not supplied in the prompt; latest verified book equity cannot be stated from the given data. | Mixed | The capital base cannot be fully measured here, so solvency analysis should stay cautious. |
Which balance-sheet risk matters most for Xylem Inc.?
Net debt is the biggest watch item, because it rose to $113B even though total debt stayed at $194B. That leaves less flexibility if cash generation slows or financing gets tighter.
- Current Exposure: $403B current assets versus $276B current liabilities, with cash of $80800M at 2026-03-31.
- Protection: The strongest buffer is the $127B working-capital cushion from current assets minus current liabilities.
- Warning Signal: Watch whether net debt stays elevated and whether goodwill and intangible assets remain a large share of total assets.
Capital efficiency
Is Xylem reinvesting capital efficiently?
Xylem appears Mixed on capital efficiency, and internal cash looks partly sufficient for reinvestment needs. The business is still funding innovation and acquisitions, but the evidence points to careful monitoring rather than clear excess cash generation.
Return quality should be judged with leverage, asset intensity, capex, working capital, and external funding needs, not one ratio alone. Xylem’s mix of R&D, manufacturing expansion, and acquisition integration makes capital efficiency more about disciplined deployment than simple earnings growth. For background on the business model, see Xylem Inc. (XYL): History, Ownership, Mission, How It Works & Makes Money.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable | Without a supplied ROIC, the check is whether operating margins, acquisition integration, and capital intensity support value creation. | Invested capital appears productive only if growth spending earns returns above its cost. |
| ROE and ROA | Unavailable | ROE can be lifted by leverage, while ROA is more sensitive to asset intensity; both need trend evidence to judge quality. | Shareholder return quality remains unclear without verified ratios and balance-sheet detail. |
| Maintenance and Growth Investment | 2025 R&D was approximately 40% of annual revenue, totaling over $350M; FMP 2025-12-31 shows Rdexpense Growth: 1538%, and 2026-03-31 shows Rdexpense Growth: -667%. Growth examples include Xylem Vue AI capabilities, AquaCase, data center thermal management, two new manufacturing hubs in Gujarat, India, the majority stake in Idrica, Heusser for approximately $40M, and Evoqua integration. | The spending mix looks growth-oriented, but the sharp R&D change means reinvestment intensity should be checked over time. | Xylem is committing real capital to innovation, manufacturing, and acquisitions, so execution matters as much as spending. |
| Internal Funding Capacity | Use operating cash flow, free cash flow, working capital, cash reserves, debt, and share issuance. Total Outstanding Shares: 243,141,405 and Number Of Shares: 24276M at 2026-03-31. | Internal funding appears important, but dilution and balance-sheet capacity need monitoring alongside cash generation. | Reinvestment looks partly internally funded, with external capital still a possible constraint if spending stays high. |
Are Xylem's returns on capital sustainable?
They may be sustainable if R&D, manufacturing, and acquisitions keep improving margins and integration stays on track. The main weakening risk is heavier reinvestment without matching cash generation or efficient asset use.
- Operating Source: Innovation spending, AI-enabled products, and water-tech mix can support margins and asset efficiency.
- Funding Requirement: The largest verified needs are R&D, manufacturing hubs, and acquisition integration.
- Durability Test: Returns weaken if R&D intensity stays volatile, cash flow lags spending, or dilution rises.
Financial resilience
How resilient is Xylem Inc. and which warning signs matter most?
Xylem Inc. looks Mixed. The main buffer is its $4615B backlog and strong cash conversion outlook. The most important verified warning sign is regional stress in China, where Fourth Quarter 2025 orders plunged 700% and headcount was cut 400% after geopolitical and competitive pressure.
Xylem Inc. has enough demand visibility to protect liquidity and funding in the near term, but resilience depends on backlog conversion and cash generation holding up. The company’s ability to keep investing will be tested if slower municipal spending, weaker regional orders, or softer margin conversion starts to hit operating cash flow.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Regional weakness can reduce operating leverage, earnings, cash flow, and debt capacity if orders stay weak or margins compress. | Recurring water infrastructure demand, a $4615B backlog, and 4Q 2025 orders of $24B support near-term revenue. | More order declines, weaker backlog conversion, or lower organic growth than the 20% to 40% 2026 guide would confirm deterioration. |
| Working-Capital or Investment Pressure | Slower project rollouts can hold up receivables and cash conversion, while growth spending can absorb cash if execution stalls. | Adjusted EBITDA margin forecast of 229%–233% and free cash flow margin forecast of 102%–110% suggest room to fund operations internally. | Weaker operating cash flow, slower backlog conversion, or rising working capital would show pressure on investment capacity. |
| Interest or Refinancing Pressure | Higher rates or refinancing needs would squeeze free cash flow and reduce financing flexibility if debt rose or liquidity tightened. | Strong backlog, cash generation, and expected revenue conversion provide a buffer if funding conditions worsen. | Any rise in interest burden, tighter liquidity, or maturity stress would signal higher financing pressure. |
Which financial warning signs should investors monitor at Xylem Inc.?
The two strongest signals are China orders and municipal rollout speed. China is a confirmed deterioration risk because Fourth Quarter 2025 orders plunged 700%; sluggish US municipal rollouts are a future risk if debt constraints keep delaying projects.
China order collapse and restructuring pressure
China is the clearest warning sign: Fourth Quarter 2025 orders fell 700% and headcount dropped 400%. That shows real regional strain. Watch order trends, not just revenue, because backlog can soften later if demand stays weak.
Guidance moderation and slower growth
Full-year 2026 revenue guidance of $91B–$92B with 20% to 40% organic growth is below full-year 2025 organic growth of 50%. Slower growth is not a crisis, but it can reduce valuation support if momentum fades again.
Municipal project delays and cash conversion
US municipal project rollouts were described as sluggish because domestic water utility districts face debt-related constraints. That matters because delays can push out revenue recognition and cash collection. Monitor backlog conversion, working capital, and free cash flow margins.
Financial Health Scorecard
What does Xylem Company’s financial health mean for investors?
Overall rating: Mixed. The strongest factor is profitability and cash generation, while the weakest is liquidity pressure from higher net debt. For investors, the most important condition is whether free cash flow stays strong enough to support growth, debt service, and resilience.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | Full-year 2025 revenue was $90B, organic growth was 50%, adjusted EPS was $508, and net income attributable to Xylem was $957M, showing solid earnings conversion. |
| Profitability and Cash | Strong | Adjusted EBITDA margin was 222%, and 2026 free cash flow margin forecast is 102%–110%, pointing to strong margin support and cash generation. |
| Balance Sheet and Liquidity | Mixed | Total Debt was $194B at 2026-03-31, Cash And Cash Equivalents fell to $80800M, and Net Debt rose to $113B, so leverage needs monitoring. |
| Capital Efficiency | Strong | R&D, integration synergies, and manufacturing localization support reinvestment, which can improve operating leverage without relying on unsupported return metrics. |
| Financial Resilience | Mixed | Backlog and margin guidance help offset China order pressure, slower 2026 growth guidance, and municipal funding constraints, but demand visibility is not fully stable. |
- What Supports the Thesis: Strong profitability, high cash generation, and margin guidance give Xylem Company room to fund growth and absorb operational pressure.
- What Challenges the Thesis: Higher net debt and weaker regional demand create uncertainty around liquidity and near-term growth.
- What to Monitor: 2026 organic growth, free cash flow margin, and net debt.
For readers using Exploring Xylem Inc. (XYL) Investor Profile: Who's Buying and Why?, these signals should shape forecasts, scenario analysis, and any DCF or valuation work.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Why does adjusted EBITDA margin matter here?
It shows whether Xylem is turning revenue into operating profit before depreciation, amortization, interest, and taxes The 222% full-year 2025 adjusted EBITDA margin and 229%–233% 2026 forecast support the view that pricing, productivity, and synergies are improving profitability
How does backlog support future cash generation?
Backlog gives investors visibility into future revenue that can later convert into billing and cash collection Xylem reported Total Backlog of $4615B at December 31, 2025, with approximately 600% expected to convert to revenue in 2026
Can Xylem self-fund more acquisitions from cash?
Xylem has meaningful cash generation goals, but investors should not assume unlimited acquisition capacity At 2026-03-31, Cash And Cash Equivalents were $80800M, Total Debt was $194B, and Net Debt was $113B, so deal funding depends on cash conversion and balance-sheet discipline
What signals would weaken Xylem liquidity?
Liquidity would look weaker if cash keeps falling, net debt rises, working capital absorbs more cash, or short-term debt becomes harder to refinance The latest balance sheet already shows lower Cash And Cash Equivalents versus 2025-12-31, so cash conversion matters
Which return measure should investors monitor most?
Investors should monitor ROIC when available because it connects operating profit to the capital invested in assets and acquisitions For Xylem, this is important because Goodwill And Intangible Assets were $1051B at 2026-03-31 after major acquisition activity